About
Sai Life Sciences states that "since its founding in 1999, Sai Life Sciences has grown from a small medicinal chemistry services provider into a trusted integrated CRDMO serving pharmaceutical and biotechnology innovators globally," spanning discovery, drug substance development and manufacturing, formulations and new modalities. Its own about page reports 27+ years of expertise, 6 global sites across the US, UK and India, 3,800+ scientists and professionals, 300+ active customers across the US, UK, EU and Japan, 19 of the 25 largest pharma companies as customers and 45 active NCE commercial / Phase III / pre-registration molecules. It was founded as Sai Dru Syn Laboratories and listed on the NSE and BSE in 2024.
Deterministic scores · rules-based, not AIiHow these scores are obtained: each one is computed from this profile's listed attributes — capability checkboxes, certifications, capacity figures and coverage — by a fixed formula, recomputed on every page load. Deterministic and rules-based means the score comes from a fixed, transparent formula over listed attributes — the same inputs always produce the same score. It is not AI: there is no model, no learning, and no hidden weighting. Whether a score is relevant to you depends on your specific project: a capability that raises the number may not matter for your work, and a niche strength your project needs may barely move it. Capability scores are a directional starting point, not a verdict. A lower score does not disqualify a company or consultant, and no decision should rest on the score alone — always contact the company directly to confirm the specifics for your project.
Manufacturing iCounts how many of the 22 core manufacturing capabilities this profile lists (7 drug-substance, 6 drug-product, 5 advanced-therapy, 4 specialized) - each adds 3.6 points, capped at 78 - plus 2.4 points per therapeutic area covered, capped at 22. Levels: 80+ Full-spectrum CDMO | 60-79 Broad capability | 40-59 Established | below 40 Focused. Whether this dimension matters for you depends on your specific project.
22Focused
Advanced therapy iCounts the 5 advanced-therapy capabilities (cell therapy, gene therapy, viral vectors, CAR-T, exosomes) at 11 points each, capped at 50, then adds bonuses for related depth: biologics drug substance 14, mRNA 12, viral vectors 10, CAR-T 8, plasmid DNA 6. Levels: 80+ ATMP leader | 60-79 Advanced | 40-59 Emerging | below 40 Limited. Whether this dimension matters for you depends on your specific project.
0Limited
Fill-finish iCounts the 6 fill-finish capabilities (vial, syringe, cartridge, blow-fill-seal, isolator, RABS) at 8 points each, capped at 42, plus 16 for sterile injectables, 12 for isolator filling, 8 for RABS. Suite count adds up to 22 more (22 at 20+ suites, 16 at 10+, 10 at 5+, 5 for any). Levels: 80+ High-capacity sterile | 60-79 Strong | 40-59 Capable | below 40 Developing. Whether this dimension matters for you depends on your specific project.
0Developing
Quality iBlends GMP certification (16), Annex 1 compliance (14) and a data-integrity program (10) with reported metrics: inspection pass rate up to 24, quality score up to 18, plus bonuses for low CAPA counts (up to 8) and few audit findings last year (up to 10 for zero). Shows Not reported (score 0) when no GMP flag, pass rate, quality score or data-integrity program is on file. Levels: 80+ Exceptional | 60-79 Strong | 40-59 Solid | below 40 Developing. Whether this dimension matters for you depends on your specific project.
0Not reported
Regulatory iCounts entries in three profile lists: regulatory history (6 points each, capped at 46), inspection authorities (7 points each, capped at 30) and geographic coverage (6 points each, capped at 24). More filings, more agencies and wider geography all raise the score. Levels: 80+ Global reach | 60-79 Multi-region | 40-59 Regional | below 40 Limited. Whether this dimension matters for you depends on your specific project.
24Limited
Capacity iTiers four scale metrics: facilities (up to 28 points at 30+), manufacturing suites (up to 24 at 40+), annual unit capacity (up to 26 at 1,000,000+) and employee count (up to 22 at 10,000+). Each metric earns partial points at lower tiers, so any reported scale contributes. Levels: 80+ Global scale | 60-79 Large | 40-59 Mid-size | below 40 Boutique. Whether this dimension matters for you depends on your specific project.
32Boutique
Capabilities
PeptidesHPAPIProcess devClinical mfgCommercial mfgTech transfer
Technology platforms
Integrated drug discovery (medicinal chemistryCADD and structural biologyDMPKin vitro/in vivo biologysafety and toxicology); processanalytical and particle science development; API manufacturing with reactors from lab scale to 10000+ L and 450 KL reactor capacity at Bidarcryogenic systemshydrogenators and lyophilization suites; dedicated HPAPI suites in Hyderabad and Bidar with containment below 1 microgram/m3 and SafeBridge Banding 3B; GMP kilo lab in Manchester (vessels to 35 Lcontainment to 1 microgram/m3); new modalities - antibody-drug conjugatespeptidesoligonucleotides and lipids; NCE formulation development and clinical formulation supplies
Therapeutic areas
OncologyMetabolic diseaseNeuroscience